Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3764379
Max Phase: Preclinical
Molecular Formula: C23H39NO19
Molecular Weight: 633.55
Molecule Type: Small molecule
Associated Items:
ID: ALA3764379
Max Phase: Preclinical
Molecular Formula: C23H39NO19
Molecular Weight: 633.55
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@@](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@@H]2O)(C(=O)O)C[C@@H]1O
Standard InChI: InChI=1S/C23H39NO19/c1-6(28)24-11-7(29)2-23(22(37)38,42-18(11)12(31)8(30)3-25)43-19-13(32)9(4-26)40-21(16(19)35)41-17-10(5-27)39-20(36)15(34)14(17)33/h7-21,25-27,29-36H,2-5H2,1H3,(H,24,28)(H,37,38)/t7-,8+,9+,10+,11+,12+,13-,14+,15+,16+,17+,18+,19-,20+,21-,23-/m0/s1
Standard InChI Key: CILYIEBUXJIHCO-UITFWXMXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 633.55 | Molecular Weight (Monoisotopic): 633.2116 | AlogP: -8.22 | #Rotatable Bonds: 11 |
Polar Surface Area: 335.08 | Molecular Species: ACID | HBA: 18 | HBD: 13 |
#RO5 Violations: 3 | HBA (Lipinski): 20 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 2.84 | CX Basic pKa: | CX LogP: -7.11 | CX LogD: -10.60 |
Aromatic Rings: 0 | Heavy Atoms: 43 | QED Weighted: 0.10 | Np Likeness Score: 1.76 |
1. Matsubara T, Onishi A, Yamaguchi D, Sato T.. (2016) Heptapeptide ligands against receptor-binding sites of influenza hemagglutinin toward anti-influenza therapy., 24 (5): [PMID:26833245] [10.1016/j.bmc.2016.01.039] |
2. Prescher H, Frank M, Gütgemann S, Kuhfeldt E, Schweizer A, Nitschke L, Watzl C, Brossmer R.. (2017) Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion., 60 (3): [PMID:28103033] [10.1021/acs.jmedchem.6b01111] |
3. Patel B,Kishor C,Houston TA,Shatz-Azoulay H,Zick Y,Vinik Y,Blanchard H. (2020) Rational Design and Synthesis of Methyl-β-d-galactomalonyl Phenyl Esters as Potent Galectin-8N Antagonists., 63 (20.0): [PMID:32809817] [10.1021/acs.jmedchem.0c00602] |
Source(1):